TABLE 3.
Mean trough concentrations for saquinavir, ritonavir, rifabutin, and 25-O-desacetyl-rifabutin
| Group, parameter, or druga | Value for parameter or trough drug concn (mean ± SEM)b |
|||||||
|---|---|---|---|---|---|---|---|---|
| Period 1 | Period 2 | |||||||
| Group 1 | ||||||||
| Time (day) | 11 | 12 | 13 | 14 | 27 | 30 | 33 | 36 |
| n | 25 | 25 | 25 | 19 | 23 | 22 | 20 | 19 |
| SQV (μg/ml) | 1.20 ± 0.13α | 1.24 ± 0.20α | 0.84 ± 0.16α | 0.74 ± 0.15α | 0.65 ± 0.08β | 0.66 ± 0.08β | 0.74 ± 0.14β | 0.45 ± 0.07β |
| RTV (μg/ml) | 0.55 ± 0.05Y | 0.57 ± 0.06Y | 0.56 ± 0.05Y | 0.49 ± 0.07Y | 0.52 ± 0.06δ | 0.44 ± 0.03δ | 0.50 ± 0.06δ | 0.38 ± 0.03δ |
| Group 2 | ||||||||
| Time (day) | 17 | 18 | 20 | NA | 34 | 37 | 40 | 43 |
| n | 14 | 14 | 11 | NA | 12 | 11 | 10 | 11 |
| RFB (ng/ml) | 37 ± 2 | 40 ± 3 | 36 ± 3 | NA | 67 ± 5 | 64 ± 4 | 64 ± 4 | 70 ± 5 |
| 25-RFB (ng/ml) | 1.4 ± 0.4 | 1.5 ± 0.5 | 1.4 ± 0.6 | NA | 57 ± 4 | 53 ± 6 | 53 ± 6 | 57 ± 5 |
| SQV (μg/ml) | NA | NA | NA | NA | 0.8 ± 0.1 | 1.3 ± 0.3 | 0.9 ± 0.3 | 0.6 ± 0.1 |
| RTV (μg/ml) | NA | NA | NA | NA | 0.66 ± 0.09 | 0.8 ± 0.1 | 0.5 ± 0.1 | 0.58 ± 0.03 |
| Group 3 | ||||||||
| Time (day) | 17 | 18 | 20 | NA | 30 | 34 | 38 | 42 |
| n | 15 | 15 | 9 | NA | 11 | 10 | 9 | 9 |
| RFB (ng/ml) | 40 ± 3 | 39 ± 3 | 39 ± 4 | NA | 47 ± 3 | 45 ± 3 | 45 ± 4 | 45 ± 5 |
| 25-RFB (ng/ml) | 1.3 ± 0.1 | 0.8 ± 0.4 | 1.3 ± 0.6 | NA | 42 ± 2 | 46 ± 3 | 47 ± 3 | 48 ± 5 |
| SQV (μg/ml) | NA | NA | NA | NA | 1.2 ± 0.1 | 1.2 ± 0.2 | 0.7 ± 0.1 | 1.2 ± 0.3 |
| RTV (μg/ml) | NA | NA | NA | NA | 0.44 ± 0.05 | 0.47 ± 0.06 | 0.39 ± 0.08 | 0.31 ± 0.04 |
a
RFB, rifabutin; 25-RFB, 25-O-desaceyl-rifabutin; SQV, saquinavir; RTV, ritonavir.
b
Statistical significance is indicated by symbols as follows: α, P < 0.01; β, P > 0.05; Y, P > 0.05; δ, P > 0.05. NA, not applicable.